US EditionPublished • loading... • Updated
GSK's Chronic Hepatitis B Therapy Shows Promise in Key ...
Bepirovirsen achieved significantly higher functional cure rates in over 1,800 patients across 29 countries, offering a potential six-month finite therapy for chronic hepatitis B.
- On 01/07/2026, GSK announced positive Phase 3 results from B-Well 1 and B-Well 2 trials for bepirovirsen, meeting primary and ranked endpoints with significantly higher functional cure rates versus placebo.
- Chronic hepatitis B affects over 250 million people and causes around 1.1 million deaths annually; current nucleoside analogues require lifelong therapy with about one percent functional cure rates, while bepirovirsen aims for a finite six-month course by targeting HBsAg.
- Enrolling 1,800 patients across 29 countries, the randomized trials gave weekly subcutaneous injections for 24 weeks and defined functional cure as sustained HBsAg loss and undetectable HBV DNA.
- GSK modelled peak sales of $2.5 billion for bepirovirsen, while Ionis Pharmaceuticals could receive $150 million in milestone payments plus royalties of 10% to 12%.
- This result is the first of five anticipated Phase 3 readouts from Ionis partnered programs this year, with full results to be submitted for scientific congress and peer‑reviewed journal and regulatory support.
Insights by Ground AI
11 Articles
11 Articles
GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B
GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life. The post GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B appeared first on MedCity News.
Coverage Details
Total News Sources11
Leaning Left1Leaning Right0Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
14%
C 86%
Factuality
To view factuality data please Upgrade to Premium
